PPARA and metabolic dysfunction-associated steatotic liver disease: More important, Zhang et al. observed that ISL mitigated NAFLD/NASH symptoms by downregulating SREBP and upregulating PPARα activities via the IQGAP2-CREB-SIRT1 axis (Zhang et al., 2021).